Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5845711 | Pulmonary Pharmacology & Therapeutics | 2015 | 7 Pages |
Abstract
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a secondary benefit in a variety of other disease processes, actions which are known as pleiotropic effects. Review of the current pulmonary literature suggests a potential advantage of statin usage in a variety of pulmonary conditions. Our paper serves as a focused discussion on the pleiotropic effects of statins in the most common pulmonary disorders.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Rama K. Krishna, Omar Issa, Debjit Saha, Francisco Yuri B. Macedo, Barbara Correal, Orlando Santana,